by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.cyclosporineMinor (1)cyclosporine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dabrafenibMonitor Closely (1)dabrafenib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.darifenacinMinor (1)darifenacin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.darunavirContraindicated (1)darunavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for serious and/or life-threatening reactions.dasatinibMonitor Closely (2)dasatinib and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and dasatinib both increase QTc interval. Use Caution/Monitor.Minor (1)dasatinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.deferasiroxMonitor Closely (1)deferasirox will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.degarelixMonitor Closely (2)degarelix and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and degarelix both decrease QTc interval. Use Caution/Monitor.delafloxacinMonitor Closely (1)delafloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.desfluraneSerious - Use Alternative (1)desflurane and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug.desipramineMonitor Closely (2)desipramine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and desipramine both increase QTc interval. Use Caution/Monitor.deutetrabenazineMonitor Closely (1)alfuzosin and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexamethasoneMinor (1)dexamethasone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.DHEA, herbalMinor (1)DHEA, herbal will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.diclofenacMonitor Closely (1)diclofenac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.diflunisalMonitor Closely (1)diflunisal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.diltiazemMonitor Closely (1)diltiazem will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased exposure to alfuzosin may be expected when alfuzosin is concomitantly used with diltiazem. Monitor pulse and blood pressure.disopyramideSerious - Use Alternative (1)alfuzosin and disopyramide both increase QTc interval. Avoid or Use Alternate Drug.dofetilideMonitor Closely (1)dofetilide and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.dolasetronMonitor Closely (2)dolasetron and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and dolasetron both increase QTc interval. Use Caution/Monitor.donepezilMonitor Closely (1)donepezil and alfuzosin both increase QTc interval. Use Caution/Monitor.doxazosinMonitor Closely (1)alfuzosin and doxazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.doxepinMonitor Closely (1)doxepin and alfuzosin both increase QTc interval. Use Caution/Monitor.dronedaroneContraindicated (1)alfuzosin and dronedarone both increase QTc interval. Contraindicated.Minor (1)dronedarone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.droperidolMonitor Closely (1)droperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.duvelisibMonitor Closely (1)duvelisib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.efavirenzMonitor Closely (1)efavirenz and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)efavirenz will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.elagolixMonitor Closely (1)elagolix will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eliglustatMonitor Closely (1)alfuzosin and eliglustat both increase QTc interval. Use Caution/Monitor.elvitegravir/cobicistat/emtricitabine/tenofovir DFContraindicated (1)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.enalaprilMonitor Closely (1)enalapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.encorafenibMonitor Closely (2)encorafenib, alfuzosin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents. encorafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and encorafenib both increase QTc interval. Avoid or Use Alternate Drug.entrectinibSerious - Use Alternative (1)alfuzosin and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.enzalutamideSerious - Use Alternative (1)enzalutamide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.eribulinMonitor Closely (1)eribulin and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and eribulin both increase QTc interval. Avoid or Use Alternate Drug.erythromycin baseMonitor Closely (2)erythromycin base and alfuzosin both increase QTc interval. Use Caution/Monitor. erythromycin base will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateMonitor Closely (2)erythromycin ethylsuccinate and alfuzosin both increase QTc interval. Use Caution/Monitor. erythromycin ethylsuccinate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateMonitor Closely (2)erythromycin lactobionate and alfuzosin both increase QTc interval. Use Caution/Monitor. erythromycin lactobionate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearateMonitor Closely (2)erythromycin stearate and alfuzosin both increase QTc interval. Use Caution/Monitor. erythromycin stearate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.escitalopramMonitor Closely (2)escitalopram and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and escitalopram both increase QTc interval. Use Caution/Monitor.eslicarbazepine acetateMinor (1)eslicarbazepine acetate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.esmololMonitor Closely (1)alfuzosin and esmolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.ethanolMinor (1)alfuzosin, ethanol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension, esp. in Asian pts.etodolacMonitor Closely (1)etodolac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.etravirineSerious - Use Alternative (1)etravirine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.fedratinibMonitor Closely (1)fedratinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.felodipineMonitor Closely (1)alfuzosin and felodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.fenoprofenMonitor Closely (1)fenoprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.fexinidazoleSerious - Use Alternative (2)fexinidazole and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval. fexinidazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fingolimodMonitor Closely (1)fingolimod and alfuzosin both increase QTc interval. Use Caution/Monitor.flecainideSerious - Use Alternative (1)alfuzosin and flecainide both increase QTc interval. Avoid or Use Alternate Drug.fluconazoleContraindicated (1)alfuzosin and fluconazole both increase QTc interval. Contraindicated.Minor (1)fluconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fludrocortisoneMinor (1)fludrocortisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fluoxetineMonitor Closely (2)fluoxetine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazineMonitor Closely (2)fluphenazine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and fluphenazine both increase QTc interval. Use Caution/Monitor.flurbiprofenMonitor Closely (1)flurbiprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.fluvoxamineMonitor Closely (1)fluvoxamine and alfuzosin both increase QTc interval. Use Caution/Monitor.formoterolMonitor Closely (2)formoterol and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and formoterol both increase QTc interval. Use Caution/Monitor.fosamprenavirContraindicated (1)fosamprenavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.fosaprepitantMinor (1)fosaprepitant will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.foscarnetMonitor Closely (1)foscarnet and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and foscarnet both increase QTc interval. Avoid or Use Alternate Drug.fosinoprilMonitor Closely (1)fosinopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.fosphenytoinMinor (1)fosphenytoin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fostemsavirMonitor Closely (1)alfuzosin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. gemifloxacinMonitor Closely (2)gemifloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and gemifloxacin both increase QTc interval. Use Caution/Monitor.gemtuzumabMonitor Closely (1)alfuzosin and gemtuzumab both increase QTc interval. Use Caution/Monitor.gilteritinibMonitor Closely (1)alfuzosin and gilteritinib both increase QTc interval. Use Caution/Monitor.glasdegibSerious - Use Alternative (1)alfuzosin and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.goserelinMonitor Closely (1)goserelin and alfuzosin both increase QTc interval. Use Caution/Monitor.granisetronMonitor Closely (1)alfuzosin and granisetron both increase QTc interval. Use Caution/Monitor.grapefruitMinor (1)grapefruit will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.griseofulvinMinor (1)griseofulvin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.haloperidolMonitor Closely (2)alfuzosin and haloperidol both increase QTc interval. Use Caution/Monitor. haloperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.histrelinMonitor Closely (1)histrelin and alfuzosin both increase QTc interval. Use Caution/Monitor.hydrocortisoneMinor (1)hydrocortisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.hydroxychloroquine sulfateSerious - Use Alternative (2)hydroxychloroquine sulfate and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. alfuzosin and hydroxychloroquine sulfate both increase QTc interval. Avoid or Use Alternate Drug.hydroxyzineMonitor Closely (1)alfuzosin and hydroxyzine both increase QTc interval. Use Caution/Monitor.ibuprofenMonitor Closely (1)ibuprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ibuprofen IVMonitor Closely (1)ibuprofen IV decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ibutilideSerious - Use Alternative (1)alfuzosin and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.idelalisibContraindicated (1)idelalisib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.iloperidoneMonitor Closely (2)iloperidone increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. iloperidone increases effects of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.Serious - Use Alternative (1)alfuzosin and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.imidaprilMonitor Closely (1)imidapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.indacaterol, inhaledMonitor Closely (2)indacaterol, inhaled and alfuzosin both increase QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias. alfuzosin and indacaterol, inhaled both increase QTc interval. Use Caution/Monitor.indapamideMonitor Closely (2)indapamide and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and indapamide both increase QTc interval. Use Caution/Monitor.indinavirContraindicated (1)indinavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.indomethacinMonitor Closely (1)indomethacin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.inotuzumabSerious - Use Alternative (2)inotuzumab and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment. alfuzosin and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug.isofluraneSerious - Use Alternative (1)alfuzosin and isoflurane both increase QTc interval. Avoid or Use Alternate Drug.isoniazidSerious - Use Alternative (1)isoniazid will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.isradipineMonitor Closely (3)isradipine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and isradipine both increase QTc interval. Use Caution/Monitor. alfuzosin and isradipine both increase anti-hypertensive channel